About RootPath Genomics
RootPath Genomics is a company based in Cambridge (United States) founded in 2017. RootPath Genomics has raised $68 million across 3 funding rounds from investors including CDH, Sky9 Capital and Matrix. The company has 16 employees as of December 31, 2022. RootPath Genomics operates in a competitive market with competitors including Celgene, Denali Therapeutics, eGenesis, MiRagen and Poseida Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 16 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rootpath Genomics
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$68 M (USD)
in 3 rounds
-
Latest Funding Round
$50 M (USD), Series B
Sep 07, 2021
-
Investors
CDH
& 7 more
-
Employee Count
16
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of RootPath Genomics
Unlock access to complete
Unlock access to complete
Funding Insights of RootPath Genomics
RootPath Genomics has successfully raised a total of $68M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $50 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RootPath Genomics
RootPath Genomics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include CDH, Sky9 Capital and Matrix.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and private debt firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Tech investments are made stage-agnostically in China and the US.
|
Locked | Locked | Locked | |
|
Early-stage ventures are funded by the investment firm.
|
Locked | Locked | Locked |
Investor details for RootPath Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RootPath Genomics
Investment portfolio details for RootPath Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RootPath Genomics
Detailed financials for RootPath Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rootpath Genomics Comparisons
Peer comparison for RootPath Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RootPath Genomics
RootPath Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Celgene, Denali Therapeutics, eGenesis, MiRagen and Poseida Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for cancer and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
Detailed competitors of RootPath Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rootpath Genomics
Complete news archive for RootPath Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RootPath Genomics
RootPath Genomics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
RootPath Genomics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
RootPath Genomics is a funded company, having raised a total of $68M across 3 funding rounds to date.
As of Dec 31, 2022, the latest employee count at RootPath Genomics is 16.
RootPath Genomics was founded in 2017 in Cambridge, United States, within the biotechnology sector. An immunotherapy platform centered on T cell therapy is operated to deliver personalized cancer treatments. Immune cells are analyzed and engineered using genetic engineering and computational biology techniques. The approach enables the creation of immune-based cell therapies tailored to individual patients, with operations focused on advancing oncology solutions.
RootPath Genomics's top competitors include Juno Therapeutics, eGenesis and Poseida Therapeutics.
RootPath Genomics has 8 investors. Key investors include CDH, Sky9 Capital, Matrix, Yuanhe Holdings, and Sequoia Capital.